# Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects

> **NCT03991299** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vanderbilt University Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Obese
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Botox 200 UNT Injection

## Key facts

- **NCT ID:** NCT03991299
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-29
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-02-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor Decision.
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991299, "Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03991299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*